汇宇制药及下属公司多项产品取得境外上市许可

Core Viewpoint - The company, Huili Pharmaceutical (688553.SH), and its subsidiaries have received marketing approvals for several pharmaceutical products from various regulatory authorities in Europe and Asia [1] Group 1: Regulatory Approvals - Huili Pharmaceutical and its subsidiaries, Seacross Pharma (Europe) Ltd. and Seacross Pharmaceuticals Ltd., have recently obtained marketing licenses for the following products: injectable paclitaxel (albumin-bound), injectable cyclophosphamide, paclitaxel injection, injectable zoledronic acid concentrated solution, and injectable azacitidine [1]